JPMorgan Chase & Co. Has $414,000 Stock Holdings in LifeMD, Inc. $LFMD

JPMorgan Chase & Co. cut its stake in LifeMD, Inc. (NASDAQ:LFMD) by 85.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,941 shares of the company’s stock after selling 351,630 shares during the period. JPMorgan Chase & Co. owned approximately 0.13% of LifeMD worth $414,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after acquiring an additional 2,235 shares in the last quarter. Creative Planning acquired a new position in LifeMD in the 2nd quarter valued at $272,000. Legal & General Group Plc raised its holdings in LifeMD by 187.4% in the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after acquiring an additional 6,614 shares in the last quarter. Rhumbline Advisers raised its holdings in LifeMD by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after acquiring an additional 4,281 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in LifeMD by 21,332.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 101,802 shares of the company’s stock valued at $1,387,000 after acquiring an additional 101,327 shares in the last quarter. 35.52% of the stock is owned by institutional investors and hedge funds.

LifeMD Stock Performance

LifeMD stock opened at $3.77 on Wednesday. LifeMD, Inc. has a 52 week low of $2.56 and a 52 week high of $15.84. The stock has a market capitalization of $180.85 million, a P/E ratio of 14.50 and a beta of 1.77. The stock has a fifty day moving average of $3.37 and a 200-day moving average of $4.14.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The business had revenue of $46.87 million for the quarter, compared to analyst estimates of $48.57 million. On average, research analysts forecast that LifeMD, Inc. will post -0.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wall Street Zen raised LifeMD from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Zacks Research raised LifeMD from a “strong sell” rating to a “hold” rating in a report on Friday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th. HC Wainwright boosted their price target on LifeMD from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of LifeMD in a report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.14.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.